Novavax (NASDAQ: NVAX) reported Q4 EPS of ($0.13), $0.01 worse than the analyst estimate of ($0.12). Revenue for the quarter came in at $6.1 million versus the consensus estimate of $7.09 million.

For earnings history and earnings-related data on Novavax (NVAX) click here.